Kan N - Search Results

1

Cellular interaction against autologous tumor cells between IL-2-cultured lymphocytes and fresh peripheral blood lymphocytes in patients with breast cancer given immuno-chemotherapy.

Yamasaki S, Kan N, Mise K, Harada T, Ichinose Y, Moriguchi Y, Kodama H, Satoh K, Ohgaki K, Tobe T. Yamasaki S, et al. Among authors: kan n. Biotherapy. 1993;6(1):63-71. doi: 10.1007/BF01877387. Biotherapy. 1993. PMID: 8507545

2

Therapeutic and life-prolonging effect of intrapleural injection with a streptococcal preparation, OK-432, and IL2-cultured effusion lymphocytes to breast cancer patients with malignant pleural effusion.

Hori T, Mise K, Kan N, Okino T, Satoh K, Yamasaki S, Teramura Y, Harada T, Ohgaki K, Kodama H, et al. Hori T, et al. Among authors: kan n. Biotherapy. 1992;5(1):21-9. doi: 10.1007/BF02194783. Biotherapy. 1992. PMID: 1389900

3

[Augmentation of therapeutic effect of adoptive immunotherapy through a synergy between transferred killer cells and host's fresh lymphocytes].

Kan N, Yamasaki S, Harada T, Satoh K, Ichinose Y, Moriguchi Y, Kodama H, Ohgaki K. Kan N, et al. Hum Cell. 1992 Sep;5(3):236-42. Hum Cell. 1992. PMID: 1467322 Japanese.

4

Factors influencing the response and survival of patients with liver metastases from breast cancer receiving OK-432-combined adoptive immunotherapy.

Yamasaki S, Okino T, Kan N, Satoh K, Mise K, Teramura Y, Harada T, Kodama H, Hori T, Ohgaki K, et al. Yamasaki S, et al. Among authors: kan n. J Cancer Res Clin Oncol. 1992;118(2):157-62. doi: 10.1007/BF01187506. J Cancer Res Clin Oncol. 1992. PMID: 1735736

5

A murine plasmacytoma MOPC 104E resistant to cyclophosphamide is resistant to immunotherapy.

Satoh K, Kan N, Okino T, Nakanishi M, Mise K, Teramura Y, Yamasaki S, Ohgaki K, Tobe T. Satoh K, et al. Among authors: kan n. Cancer Immunol Immunother. 1991;32(5):273-9. doi: 10.1007/BF01789044. Cancer Immunol Immunother. 1991. PMID: 1998969 Free PMC article.

6

Comparison between crude interleukin-2 and recombinant interleukin-2 in maintaining killing activity of cultured lymphocytes.

Nakanishi M, Kan N, Okino T, Satoh K, Mise K, Teramura Y, Yamasaki S, Ohgaki K, Tobe T. Nakanishi M, et al. Among authors: kan n. Biotherapy. 1990;2(1):21-32. doi: 10.1007/BF02172073. Biotherapy. 1990. PMID: 2119201

7

The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from breast cancer.

Okino T, Kan N, Nakanishi M, Satoh K, Mise K, Teramura Y, Yamasaki S, Hori T, Kodama H, Ohgaki K, et al. Okino T, et al. Among authors: kan n. J Cancer Res Clin Oncol. 1990;116(2):197-202. doi: 10.1007/BF01612677. J Cancer Res Clin Oncol. 1990. PMID: 2324164

8

[Experimental study on the optimal treatment schedule for combination of BRM (immunostimulators, cultured killer cells or interleukin-2) and chemotherapy].

Kan N, Okino T, Satoh K, Mise K, Teramura Y, Yamasaki S, Harada T, Ohgaki K, Tobe T. Kan N, et al. Gan To Kagaku Ryoho. 1990 Aug;17(8 Pt 1):1421-7. Gan To Kagaku Ryoho. 1990. PMID: 2389941 Japanese.

9

Effect of heat treatment on tumor cells and antitumor effector cells.

Mise K, Kan N, Okino T, Nakanishi M, Satoh K, Teramura Y, Yamasaki S, Ohgaki K, Tobe T. Mise K, et al. Among authors: kan n. Cancer Res. 1990 Oct 1;50(19):6199-202. Cancer Res. 1990. PMID: 2400985

10

Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes and in vivo IL2 against advanced murine plasmacytoma.

Kan N, Okino T, Nakanishi M, Sato K, Mise K, Yamasaki S, Teramura Y, Ohgaki K, Tobe T. Kan N, et al. Biotherapy. 1989;1(3):197-206. doi: 10.1007/BF02170888. Biotherapy. 1989. PMID: 2642023

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

243 results

Search Page

Filters